Research graph
References from Hypofractionated image guided radiation therapy followed by prostate seed implant boost for men with newly diagnosed intermediate and high risk adenocarcinoma of the prostate: Preliminary results of a phase 2 prospective study. Local targets link to admitted publications; unresolved targets remain external evidence.
National Institutes of Health Consensus Development Conference on the Management of Clinically Localized Prostate Cancer. Bethesda, MD, June 15-17, 1987
1988 · External reference
Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer
10.1016/j.ijrobp.2007.06.054 · 2008 · External reference
Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy
10.1200/jco.2005.05.2530 · 2006 · External reference
Prostate cancer radiation dose response: Results of the M. D. Anderson phase III randomized trial
10.1016/s0360-3016(02)02829-8 · 2002 · External reference
Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial
10.1001/jama.294.10.1233 · 2005 · External reference
Combination of IG-IMRT and permanent source prostate brachytherapy in patients with organ-confined prostate cancer: GU and GI toxicity and effect on erectile function
10.1016/j.brachy.2010.09.004 · 2011 · External reference
Brachytherapy versus brachytherapy plus external beam radiation for prostate cancer: A comparison of urinary symptoms and quality of life
10.1016/s0360-3016(03)01319-1 · 2003 · External reference
Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: Long-term results of CALGB 99809
10.1002/cncr.26203 · 2011 · External reference
Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy
10.1002/cncr.20446 · 2004 · External reference
Long-term treatment related complications of brachytherapy for early prostate cancer: A survey of patients previously treated
10.1016/s0022-5347(05)65970-8 · 2001 · External reference
Gastrointestinal toxicity of transperineal interstitial prostate brachytherapy
10.1016/s0360-3016(01)02811-5 · 2002 · External reference
Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy
10.1002/cncr.11595 · 2003 · External reference
Urinary morbidity following ultrasound-guided transperineal prostate seed implantation
10.1016/s0360-3016(99)00176-5 · 1999 · External reference
Rectal complications associated with transperineal interstitial brachytherapy for prostate cancer
10.1016/s0360-3016(00)00632-5 · 2000 · External reference
Long-term results of an RTOG Phase II trial (00-19) of external-beam radiation therapy combined with permanent source brachytherapy for intermediate-risk clinically localized adenocarcinoma of the prostate
10.1016/j.ijrobp.2011.11.040 · 2012 · External reference
Comparison of high-dose (86.4 Gy) IMRT vs combined brachytherapy plus IMRT for intermediate-risk prostate cancer
10.1111/bju.12514 · 2014 · External reference
Prostate cancer, version 1.2016
10.6004/jnccn.2016.0004 · 2016 · External reference
Fractionation and protraction for radiotherapy of prostate carcinoma
10.1016/s0360-3016(98)00438-6 · 1999 · External reference
The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: Morbidity outcomes from two prospective randomized multicenter trials
10.1016/s0360-3016(02)04527-3 · 2003 · External reference
Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: Results of a matched pair analysis
10.1002/pros.20118 · 2005 · External reference
Combined brachytherapy with external beam radiotherapy for localized prostate cancer: Reduced morbidity with an intraoperative brachytherapy planning technique and supplemental intensity-modulated radiation therapy
10.1016/j.brachy.2007.12.002 · 2008 · External reference
Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?
10.1016/j.ijrobp.2012.03.004 · 2013 · External reference
Is the alpha/beta ratio for prostate tumours really low and does it vary with the level of risk at diagnosis?
2013 · External reference
Dosimetry and preliminary acute toxicity in the first 100 men treated for prostate cancer on a randomized hypofractionation dose escalation trial
10.1016/j.ijrobp.2005.07.970 · 2006 · External reference
Rationale, conduct, and outcome using hypofractionated radiotherapy in prostate cancer
10.1016/j.semradonc.2008.04.007 · 2008 · External reference
Hypofractionated radiotherapy for localised prostate cancer. Review of clinical trials
10.1007/s12094-009-0382-2 · 2009 · External reference
Hypofractionated intensity modulated irradiation for localized prostate cancer, results from a phase I/II feasibility study
10.1186/1748-717x-2-29 · 2007 · External reference
Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomes
10.1016/j.ijrobp.2005.05.054 · 2005 · External reference
Updated results and patterns of failure in a randomized hypofractionation trial for high-risk prostate cancer
10.1016/j.ijrobp.2012.02.049 · 2012 · External reference
Randomized trial of hypofractionated external-beam radiotherapy for prostate cancer
10.1200/jco.2013.51.1972 · 2013 · External reference
NRG Oncology RTOG 0415: A randomized phase 3 noninferiority study comparing 2 fractionation schedules in patients with low-risk prostate cancer
10.1016/j.ijrobp.2015.10.049 · 2015 · External reference
Stereotactic body radiotherapy for primary management of early-stage, low- to intermediate-risk prostate cancer: Report of the American Society for Therapeutic Radiology and Oncology Emerging Technology Committee
10.1016/j.ijrobp.2009.09.078 · 2010 · External reference
Stereotactic body radiotherapy for low-risk prostate cancer: Five-year outcomes
10.1186/1748-717x-6-3 · 2011 · External reference
Image-guided stereotactic body radiation therapy for localized prostate cancer
10.1177/030089161109700109 · 2011 · External reference
Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: First clinical trial results
10.1016/j.ijrobp.2006.10.050 · 2007 · External reference
Stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer: The Georgetown University experience
10.1186/1748-717x-8-58 · 2013 · External reference
Stereotactic body radiotherapy for localized prostate cancer: Disease control and quality of life at 6 years
10.1186/1748-717x-8-118 · 2013 · External reference
Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials
10.1016/j.radonc.2013.08.030 · 2013 · External reference
Stereotactic body radiotherapy for primary prostate cancer: A systematic review
10.1111/1754-9485.12213 · 2014 · External reference
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
10.1016/j.ijrobp.2006.04.029 · 2006 · External reference
Biologically effective dose values for prostate brachytherapy: Effects on PSA failure and posttreatment biopsy results
10.1016/j.ijrobp.2005.07.981 · 2006 · External reference
Comparison of biological effective dose between protons and seed implant plus IMRT for prostate treatment
10.1118/1.3181483 · 2009 · External reference
The alpha/beta ratio for prostate cancer: What is it, really?
10.1016/j.radonc.2005.06.009 · 2005 · External reference
Alpha/beta value and importance of dose per fraction for the late rectal and recto-sigmoid complications
1993 · External reference
The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes
10.1111/bju.12166 · 2013 · External reference
Phase I/II trial of single-fraction high-dose-rate brachytherapy-boosted hypofractionated intensity-modulated radiation therapy for localized adenocarcinoma of the prostate
10.1016/j.brachy.2011.07.006 · 2012 · External reference
The best method for dose escalation: Prostate brachytherapy
10.5489/cuaj.12121 · 2012 · External reference
Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death
10.1002/cncr.22341 · 2007 · External reference
Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure
10.1016/j.urology.2006.08.1056 · 2006 · External reference
